Skip to main content

Day: December 8, 2022

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

MINNEAPOLIS, Dec. 08, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company’s Special Meeting of Stockholders, on December 7, 2022 at 2:00 p.m. (CST), was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of one-third of the outstanding shares entitled to vote. There were fewer than one-third of outstanding shares entitled to vote, either present virtually or represented by proxy, at the Special Meeting. The Special Meeting therefore had no quorum and was adjourned to 2:00 p.m. Central Time on January 4, 2023 at www.viewproxy.com/nuwesm/2022 to allow additional time for the Company’s stockholders to vote on the proposals set forth in the...

Continue reading

Anders Örnulf is leaving as CFO for SkiStar

SkiStar AB (publ)’s CFO Anders Örnulf has today announced that he will terminate his employment with SkiStar for a new assignment for another company. Anders, who has been SkiStar’s CFO since 2018, will continue in his position as CFO until a successor takes office, or until June 2023 at the latest. SkiStar will immediately start the recruitment process of a replacement. “During his five years at SkiStar, Anders Örnulf has had a prominent role in the company’s development, especially in such a turbulent period as the pandemic has brought. I would like to extend a big thank you to Anders, who is highly valued both as a skilled CFO for the company and as a colleague. We wish him all the best when he later leaves SkiStar,” says Stefan Sjöstrand, CEO at SkiStar. “My time at SkiStar has been extremely stimulating and...

Continue reading

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British Society for Immunology Congress 2022 OCALA, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported that data were recently presented by Lisanne C.A. Smidt – Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity...

Continue reading

Form 8.3 – [EMIS Group plc – 07 12 2022] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED formerly HARGREAVE HALE LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Energy Management Systems Market Size Projected to Grow $75.0 Billion by 2027 growing at a CAGR of 14.2%

Chicago, Dec. 08, 2022 (GLOBE NEWSWIRE) — Energy Management Systems Market is projected to grow from USD 38.6 billion in 2022 to USD 75.0 billion by 2027, at a CAGR of 14.2% according to a new report by MarketsandMarkets™. The growth of the energy management systems market is proportional to the installation of smart grids and smart meters. Also, the increasing energy consumption as well as the price volatility of energy resources plays a major role in driving the growth of energy management systems. The energy management systems market is expected to witness significant growth during the forecast period. With such a high demand for energy resources, the volatility in energy prices centers on changes in supply and demand. Economic conditions, availability of energy resources, and increasing demand are the prime factors...

Continue reading

Alm. Brand A/S – Award of share-based remuneration

Alm. Brand – Award of share-based remuneration In accordance with the Alm. Brand Group’s remuneration policy Alm. Brand A/S, effective from 1 July 2016, has entered into an agreement with the Management Board and other members of the group’s extended management team under which up to 10% of the fixed salary may be allotted by way of shares. Shares are awarded twice annually, on the third trading day of June and the third trading day of December. The value of the awarded shares has been calculated as a simple average of the average price quoted for one share on the first trading day of each calendar month forming the basis of the award. A total of 486,087 shares representing a total market value of DKK 5,137,939.59 have been awarded. The shares are freely negotiable instruments. The agreement on share-based remuneration applies until...

Continue reading

Transformation and Technology Expert Timothy Wilde Joins UpHealth as Chief Technology Officer

DELRAY BEACH, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) — Healthcare transformation expert Timothy Wilde has joined UpHealth, Inc. (NYSE: UPH) as Chief Technology Officer, effectively immediately. Wilde reports to UpHealth CEO Sam Meckey and will be part of the company’s executive leadership team. Wilde, who has 30 years of experience across the healthcare, genomics, life sciences and insurance sectors, most recently served as Chief Technology Officer for EXL Health. There, he led business transformation for the company’s digital, clinical, payments and data and analytics clients and was responsible for an order of magnitude increase in digital health revenue, while also improving net income technology costs. “Tim’s expertise will be a tremendous asset to UpHealth,” said Meckey. “He has a long history in healthcare in both the payer...

Continue reading

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th. The clinical team at Southampton University in the UK, led by Professor Kim Orchard, the past president of the British Society of Blood and Marrow Transplantation and Cellular Therapy, is the first author of the presentation. The poster presents findings from patients who have received INKmune therapy for treatment of their AML/MDS and provides additional information on the biologic changes that occur in...

Continue reading

gategroup commits to 100% cage-free eggs globally by 2025

As the global leader in airline catering, retail-on-board and food service, gategroup has the commitment to helping build a better future. As part of this undertaking, we have pledged to make our entire egg supply chain cage-free by 2025. Our pledge All egg (shell egg, liquid egg and mixes containing more than 80% egg) purchases globally will conform to certified standards of animal welfare that meet or exceed those dictated by local legislation. Our global, group-wide, minimum welfare standard is ‘barn’ (cage-free) eggs. We are working with our partners and suppliers to achieve our goal of 100% cage-free eggs throughout the Group by 2025. Rising to the challenge gategroup has worked hard towards our cage-free eggs ambition over the last years to achieve more than 75% cage-free eggs globally. To achieve our goals, we are confronting the...

Continue reading

Form 8.3 – [Devro plc – 07 12 2022] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.